Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Integrated Summary of Immunogenicity (ISI) Preparation for EMA Biologics License Application (BLA) Submissions

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Integrated Summary of Immunogenicity (ISI) Preparation for EMA Biologics License Application (BLA) Submissions

Integrated Summary of Immunogenicity (ISI) for EMA Biologics Submissions

CELL & GENE | RNA | BIOLOGICS

Frequently Asked Questions (FAQ)

    What is the primary purpose of the Integrated Summary of Immunogenicity (ISI) in an EMA BLA submission?

    A: The ISI provides a comprehensive, integrated analysis of all immunogenicity data from nonclinical and clinical studies. Its purpose is to build a cohesive narrative that characterizes the immunogenicity profile of a biologic and assesses its impact on pharmacokinetics, pharmacodynamics, safety, and efficacy for European regulators.

    How does the EMA’s expectation for the ISI differ from the FDA’s?

    A: While both agencies require a thorough immunogenicity assessment, the EMA places a distinct emphasis on the integrated narrative and the clinical relevance of observed immunogenicity. The EMA expects the summary to proactively interpret data and justify the risk assessment, moving beyond the presentation of disparate datasets from individual studies.

    What are the key data components required for a robust ISI for a cell or gene therapy?

    A: A robust ISI for an advanced therapy must include data from a multi-tiered testing strategy (screening, confirmatory, titration), neutralizing antibody (NAb) assays, characterization of anti-drug antibody (ADA) responses (e.g., isotype, domain specificity), and a clear correlation of ADA incidence and titer with clinical outcomes.

    How should potential clinical sequelae of immunogenicity be addressed in the ISI?

    A: The ISI must directly address and interpret any observed or potential clinical consequences. This includes analyzing correlations between ADA status and adverse events, hypersensitivity reactions, loss of efficacy, or altered PK/PD profiles. A clear risk mitigation strategy based on these findings is expected.

The European regulatory authority, the EMA, requires a comprehensive Integrated Summary of Immunogenicity (ISI) that synthesizes all immunogenicity data into a cohesive, interpretive narrative. Preparing a successful ISI for a Biologics License Application (BLA) involves a multi-faceted strategy that connects nonclinical data with clinical outcomes. This requires validated, multi-tiered bioanalytical assays and a deep understanding of how to interpret immunogenicity’s impact on the product’s overall benefit-risk profile. Franklin Biolabs provides the GxP-compliant bioanalytical testing and strategic interpretation necessary to construct a submission-ready ISI for advanced biologic programs.

The Strategic Framework for an EMA-Compliant ISI

An effective ISI for an EMA submission synthesizes all immunogenicity data into a single, interpretive document. The analysis must evaluate the incidence, titer, and persistence of anti-drug antibodies (ADAs) and their clinical relevance. This evaluation is built upon a rigorously validated, multi-tiered testing cascade that includes screening, confirmatory, and neutralizing antibody assays.

A detailed characterization of the immune response supports the clinical interpretation. Key considerations for the ISI include:

  • The timing of ADA development relative to dosing.

  • The impact of ADAs on drug exposure (pharmacokinetics).

  • Correlation of ADA presence with safety signals or loss of efficacy.

  • An assessment of risk factors that may predispose patients to an immune response.

A blue-toned image of white lab rats in their cages within a laboratory or vivarium setting, likely for scientific research or testing.

A close-up shot of a modern bioreactor system and control unit from Pall Corporation in a clean laboratory environment.

Integrating Bioanalytical Data into a Cohesive Narrative

The strength of an ISI lies in its interpretation. Data from disparate sources must be woven together to explain the complete immunogenicity picture. This level of analysis is the core of our Immunogenicity Intelligence for Advanced Therapies. For example, insights from non-target tissue biodistribution studies can inform the interpretation of unexpected immune responses observed in the clinic.

Similarly, the methodologies used to generate data are as important as the data themselves. As demonstrated in advanced histology for gene therapies [PMID: 29848071], specialized sample processing protocols are necessary to preserve tissue integrity for accurate evaluation. This principle extends directly to bioanalysis: meticulous sample handling and validated GxP assays ensure the ADA and NAb data forming the foundation of the ISI are reliable and defensible under regulatory scrutiny. GxP bioanalysis is performed in our >100,000 sq ft facility, which is designed for these exacting standards.

[Video: FBL-VID-02-Approved_enhanced_affordable_clip_long.mp4]

From Data Points to Regulatory Approval

A fragmented approach to immunogenicity assessment creates significant risk during regulatory review. We structure programs to build the ISI narrative from the earliest stages of development, supporting an accelerated 18-24 month IND timeline. This integrated strategy has been a component of our 100% IND application success rate since 2019. (The Franklin Biolabs brand was launched in 2024).

The table below contrasts a siloed approach with the integrated strategy required by the EMA.

Feature Siloed Data Approach Integrated Narrative Approach
Data Presentation Separate reports for each study Synthesized analysis across studies
Risk Assessment Inferred by the reviewer Explicitly stated and justified
Clinical Context ADA data presented in isolation ADA data correlated with PK/PD & safety
Regulatory Outcome High risk of questions and delays Clear, defensible immunogenicity profile

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities